Solid biosciences reports positive initial clinical data from next-generation duchenne gene therapy candidate sgt-003

— day 90 biopsy data reported from first 3 participants dosed in phase 1/2 inspire duchenne trial —— average microdystrophin expression of 110% (n=3) and significant improvements in multiple additional muscle health biomarkers observed support the potential of sgt-003 as a next-generation, best-in-class duchenne muscular dystrophy gene therapy candidate —— encouraging early signals of potential cardiac benefit observed ——sgt-003 has been well-tolerated in the 6 participants dosed as of february 11, 2025, with no serious adverse events observed —— participant enrollment continues, with the 7th participant dosed on february 17, 2025; company expects to dose approximately 20 total participants by q4 2025 —— in mid-2025, company plans to request an fda meeting to discuss potential accelerated approval pathway for sgt-003 —— company to hold a conference call today at 8:00 am et —
SLDB Ratings Summary
SLDB Quant Ranking